Norges Bank’s Clearside Biomedical CLSD Stock Holding History

Norges Bank’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,112	Closed	-$417K	–	2145
2016 Q4	$417K	Buy	+3,112	New	+$781K	﹤0.01%	2123

Other funds holding CLSD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Norges Bank's CLSD Position: Q1 2017 in Review

Norges Bank sold out of Clearside Biomedical (CLSD) in Q1 2017, closing a stake of 3,112 shares — an estimated $417K sold.

Norges Bank first reported a position in CLSD in Q4 2016 and held it in 1 quarter. The position peaked at $417K in Q4 2016. 59 funds tracked by Wall St. Rank hold CLSD as of Q1 2017.

Norges Bank reported no remaining Clearside Biomedical position as of Q1 2017 after selling out during the quarter.
Norges Bank sold 3,112 Clearside Biomedical shares in Q1 2017, an estimated $417K.
Norges Bank first reported a position in Clearside Biomedical in Q4 2016 and held it in 1 quarter.
Norges Bank's Clearside Biomedical position peaked at $417K in Q4 2016.
59 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2017.

Based on Norges Bank's 13F filing for Q1 2017, filed 10 May 2017.